Hemolytic disease of the fetus and newborn caused by anti-Hr0 in a 27-year-old female with Dc- phenotype: A case report

Sarihi, Reyhaneh; Ahmadnejad, M.; Mohammadi, Soheil; Eshghi, Peyman; Herfat, Fahimeh; Jolharnejad, S.; Oodi, Arezoo

doi:10.1016/j.transci.2020.102913

Cited by 1 publication

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 Anti-Rh17 antibodies can be made by individuals with missing or varied C/c, E/e antigens such as the phenotypes: D--, DÁÁ, Dc-, DC W -. 4 Finding compatible blood for patients with anti-Rh17 can be particularly difficult given that less than 1 in 100,000 people are Rh17 negative. 5 The anti-Rh17 antibody has been reported in a variety of populations, and there have been case reports of hemolytic disease of the fetus and newborn (HDFN) ranging from mild to severe.…”

Section: Introductionmentioning

confidence: 99%

“…5 The anti-Rh17 antibody has been reported in a variety of populations, and there have been case reports of hemolytic disease of the fetus and newborn (HDFN) ranging from mild to severe. 4,6,7 Alternatives to blood transfusion including hemoglobin-based oxygen carriers (HBOCs) such as HBOC-201 (hemoglobin glutamer-250 [bovine]; "Hemopure," HbO2 Therapeutics LLC, Souderton, PA) have been developed to treat patients with severe anemia in which transfusion is not an option. 8 However, despite approval for use in countries such as Russia and South Africa, HBOC-201 in the United States is only available through the FDA's expanded access program.…”

Section: Introductionmentioning

confidence: 99%

“…Rh17, also known as Hr 0 , is a high‐frequency antigen, with a prevalence of almost 100%, composed of several epitopes on the RhCE protein 3 . Anti‐Rh17 antibodies can be made by individuals with missing or varied C/c, E/e antigens such as the phenotypes: D‐ ‐, D⋅⋅, Dc‐, DC W ‐ 4 . Finding compatible blood for patients with anti‐Rh17 can be particularly difficult given that less than 1 in 100,000 people are Rh17 negative 5 .…”

Section: Introductionmentioning

confidence: 99%

“…Finding compatible blood for patients with anti‐Rh17 can be particularly difficult given that less than 1 in 100,000 people are Rh17 negative 5 . The anti‐Rh17 antibody has been reported in a variety of populations, and there have been case reports of hemolytic disease of the fetus and newborn (HDFN) ranging from mild to severe 4,6,7 . Alternatives to blood transfusion including hemoglobin‐based oxygen carriers (HBOCs) such as HBOC‐201 (hemoglobin glutamer‐250 [bovine]; “Hemopure,” HbO2 Therapeutics LLC, Souderton, PA) have been developed to treat patients with severe anemia in which transfusion is not an option 8 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Transfusion management and hemoglobin‐based oxygen carrier treatment in a patient with anti‐Rh17 antibody

Mehr,

Fuja,

Simon

et al. 2024

Transfusion

View full text Add to dashboard Cite

BackgroundA 54‐year‐old Hispanic OPos female with known history of anti‐Rh17 antibodies was diagnosed with Philadelphia‐Chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Rh17, also known as Hr0, is a high‐frequency antigen composed of several epitopes on the RhCE protein. Anti‐Rh17 antibodies can be made by individuals with missing or varied C/c, E/e antigens. Anti‐Rh17 antibodies are clinically significant given multiple case reports of hemolytic disease of the fetus and newborn (HDFN). Finding compatible units for patients with anti‐Rh17 can be particularly difficult given that only 1 in 100,000 people are Rh17 negative.Study Design and MethodsSearch for compatible units was conducted by the American Rare Donor Program (ARDP) with no leads. After chemotherapy induction and despite erythropoiesis stimulating agent administration, the patient's hemoglobin continued to trend down to a nadir of 2.8 g/dL. Here we report transfusion of incompatible pRBC to this patient with critically symptomatic anemia. HBOC‐201 (Hemopure) was obtained and administered under an emergency compassionate/expanded access designation from the Food and Drug Administration (FDA) under an emergency Investigational New Drug (IND) application.Results and DiscussionOverall difficulties in this case included the challenge of finding compatible units, dilemma of transfusing incompatible units in a patient with severe anemia and obtaining alternatives to blood products. This case report demonstrates the successful use of HBOC‐21 in treating life‐threatening anemia.

show abstract

Section: Introductionmentioning

confidence: 99%